Adma Biologics Inc. (NASDAQ: ADMA) stock declined by 1.32% at the last close whereas the ADMA stock price gains by 11.40% in the pre-market trading session. ADMA Biologics is a full-service commercial pharmaceutical business focused on researching, producing, and selling specialized plasma-derived biologics for the therapy of immunocompromised patients and those at risk of infection.
>> 7 Top Picks for the Post-Pandemic Economy <<
What’s happening with ADMA stock?
ADMA Biologics confirmed today that its ADMA BioCenters plasma gathering facility in Maryville, Tennessee, has been approved by the US Food and Drug Administration. In the fourth quarter of 2020, this plasma collection plant began operations and began collecting source plasma. This facility is now FDA-licensed to gather and bring human source plasma into interstate commerce for further processing in the United States, pursuant to today’s approval.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
Read More
This brand-new plasma collection center boasts computerized registration, high-tech collection equipment that speeds up the donation process, a free Wi-Fi wireless network in the donor collection area, individual flat-screen TVs with cable for each donor station, and extremely qualified and educated staff who prioritize donor comfort and safety. The plasma facility intends to have a team of 50 highly qualified healthcare personnel when it is fully operational. The Haemonetics NexSys Persona plasma collection system has been authorized for usage at this facility.
Adam Grossman, President and Chief Executive Officer of ADMA commented,
The licensing of this plasma collecting facility is a significant step forward in ADMA’s efforts to improve end-to-end management of manufacturing processes and secure raw material plasma supply. ADMA has eight plasma collection facilities under its group name, including three FDA-approved facilities, with five of them open and collecting plasma and two more Biologics License Applications submissions expected in the second half of 2021. By 2024, ADMA hopes to establish at least ten FDA-approved plasma collecting facilities. ADMA thinks it is protected from wider market plasma collection and pricing changes due to the continuation of third-party supply agreements until year-end 2022, as well as the projected yield increases coming from their recent adoption of Haemonetics’ NexSys Persona technology. The Company is at a valuable position to secure the supply of plasma goods and the continuation of their supply chain.
